Ventyx Biosciences (NASDAQ:VTYX) Announces Earnings Results

by · The Cerbat Gem

Ventyx Biosciences (NASDAQ:VTYX – Get Free Report) announced its earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.13, Zacks reports.

Ventyx Biosciences Stock Performance

VTYX stock traded down $0.59 during midday trading on Friday, reaching $8.68. 2,204,881 shares of the company’s stock traded hands, compared to its average volume of 2,132,228. The firm has a market capitalization of $618.61 million, a PE ratio of -5.16 and a beta of 1.23. The company has a 50-day moving average price of $4.08 and a two-hundred day moving average price of $2.85. Ventyx Biosciences has a 52 week low of $0.78 and a 52 week high of $9.50.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP purchased a new position in Ventyx Biosciences during the 2nd quarter valued at about $5,129,000. AQR Capital Management LLC boosted its holdings in Ventyx Biosciences by 925.6% in the 1st quarter. AQR Capital Management LLC now owns 880,222 shares of the company’s stock valued at $1,012,000 after purchasing an additional 794,401 shares during the period. Vanguard Group Inc. boosted its holdings in Ventyx Biosciences by 19.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,769,997 shares of the company’s stock valued at $11,725,000 after purchasing an additional 607,725 shares during the period. Acadian Asset Management LLC grew its position in shares of Ventyx Biosciences by 443.8% during the 1st quarter. Acadian Asset Management LLC now owns 537,054 shares of the company’s stock valued at $614,000 after purchasing an additional 438,286 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in shares of Ventyx Biosciences by 723.7% in the second quarter. Jane Street Group LLC now owns 400,597 shares of the company’s stock worth $857,000 after purchasing an additional 351,962 shares during the period. Institutional investors own 97.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on VTYX. Oppenheimer increased their price target on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a research report on Monday, October 27th. Wells Fargo & Company increased their target price on shares of Ventyx Biosciences from $11.00 to $14.00 and gave the company an “overweight” rating in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. HC Wainwright raised Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Wednesday. Finally, Wall Street Zen raised Ventyx Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.33.

Get Our Latest Report on Ventyx Biosciences

Ventyx Biosciences Company Profile

(Get Free Report)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.

Read More